

28 October 2015

Suite 1, 1233 High Street
Armadale VIC 3142

Imugene Receives \$755K Research and Development Tax Refund

Imugene Limited (ASX:IMU) has received a research and development tax refund of \$755,854 as part of the Australian government's R&D incentive program.

These funds complement Imugene's \$3 million capital raising announced in September and will contribute to the progression of the company's main asset, HER-Vaxx, due to enter additional human Phase Ib/II gastric cancer clinical trials in 2016.

"This is valuable non-dilutive capital for Imugene. If we succeed in commercialising HER-Vaxx, it will mean a potential Australian blockbuster drug and a better treatment for people who suffer HER2-positive gastric, breast and other cancers," said Ms Leslie Chong, Chief Operating Officer of Imugene.

"Australia is a great source of medical innovations and this funding helps our company and others to convert those innovations to commercial tangible outcomes."

Leslie Chong
Chief Operating Officer
Tel: +61 458 040 433
Leslie.Chong@imugene.com
www.imugene.com

Paul Hopper
Executive Chairman
Tel: +61 406 671 515
receptogen@earthlink.net

Media contact:
Rudi Michelson
Monsoon Communications
+61 3 9620 3333
rudim[il]@monsoon.com.au

About Imugene: Imugene (ASX: IMU) is an immuno-oncology biopharmaceutical company developing HER2 positive gastric and breast cancer immunotherapies. The Company's lead product is HER-Vaxx, a proprietary HER2 positive cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu. HER-2/neu is a known and validated receptor over-expressed on various tumours including gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has successfully completed a Phase I study in patients with breast cancer and the next stage of development will be a Phase Ib/II study in patients with gastric cancer. Imugene's corporate headquarters are located in Melbourne, Australia with the scientific team in Vienna, Austria.